HOME >> BIOLOGY >> NEWS
Genome-wide mouse study yields link to human leukemia

s.

While it was Caligiuri's laboratory that designed the mouse model, it was Plass who supervised the methylation studies. He and his colleagues used a system called Restriction Landmark Genome Sequencing (RLGS) to compare methylation patterns among the three groups of mice a method of using enzymes and gel electrophoresis to map tiny bits of DNA on a grid. The stretches of DNA, referred to as fragments, show up as smudgy blobs on a test film. If a fragment is dark and definite, it is not methylated. If, on the other hand, it loses at least 30 percent of its intensity, it is regarded as methylated.

In the study, the research team tested 2447 fragments in each animal. They found anywhere from 45 to 209 (.8 percent to 8.5 percent) of the fragments methylated in the mice with cancer, but only one or two methylated fragments in the other mice.

"Interestingly, that same range of methylated fragments is exactly what we find in human leukemia, too," says Caligiuri, "so that gives added merit to our mouse model as an investigative tool."

Using data from the methylation studies, Caligiuri and Plass were able to identify a particular stretch of DNA, called Id4, as a tumor suppressor gene.

Tumor suppressor genes help control cancer by identifying and getting rid of defective cells before they have a chance to mature and divide. When tumor suppressor genes lose that ability as they can if they are silenced through methylation or some other process, it gives cancer a chance to establish a foothold and spread.

Caligiuri says much more work needs to be done, but adds that the identification of Id4 as a likely tumor suppressor gene gives clinicians another possible target for intervention.

"We already have a drug, decitabine, that we know can reverse the effects of methylation," says Plass. "We are just beginning to figure out how it best works in humans, but simply knowing that we have a new target that may be meanin
'"/>

Contact: Michelle Gailiun
Gailiun.1@osu.edu
614-293-3737
Ohio State University
20-Feb-2005


Page: 1 2 3

Related biology news :

1. Genome-wide search unearths surprising clues for diabetes and triglycerides
2. OHSU turns mouse into factory for human liver cells
3. Virtual mouse brains now available online
4. New approaches to endometriosis treatment -- mouse experiments point the way
5. New mouse model closely mimics human cancers
6. Statin treatment improves spatial memory in mouse models of Alzheimers
7. Treatment extends survival in mouse model of spinal muscular atrophy
8. UCSF stem cell study reveals cells capability in mouse brain tissue repair
9. Mutant mouse provides insights into breast cancer
10. Mapping the mouse genome
11. MRSA vaccine shows promise in mouse study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Genome wide mouse study yields link human leukemia

(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
(Date:5/26/2015)... Pharmaco-Kinesis Corporation (PKC) announced today that its ... on the Beach in Santa Monica, CA ... Company,s innovative Metronomic Biofeedback Pump (MBP), a fully smart ... time to a target site of the human body ... in real-time.  ...
(Date:5/26/2015)... JERUSALEM , May 26, 2015 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has submitted the study protocol for the company,s ... to the U.S. Food and Drug Administration (FDA). The ... Drug (IND) application. The Phase IIb study ...
(Date:5/26/2015)... Just the characterization of being a new breakthrough ... not guarantee immediate acceptance. In particular, a new ... failures is often met with significant skepticism. The ... that is often an unappreciated aspect of scientific innovation. ... has found that building acceptance of its new ...
(Date:5/22/2015)... , May 22, 2015  Actavis plc (NYSE: ... U.S. Court of Appeals for the Second Circuit has ... injunction requiring the Company to continue distribution of NAMENDA ... - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO   "While we ... ruling, we intend to continue our strong efforts to ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8
Cached News: